



EXPRESS SCRIPTS®

**Express Scripts, Inc.  
Pharmacy and Therapeutics Committee  
Proceedings  
August 20, 2009**

**New Drug Evaluations**

The Committee reviewed the following new drugs.

- A. Effient™ (prasugrel tablets) – Eli Lilly/Daiichi Sankyo**
- B. Onglyza™ saxagliptin tablets) - Bristol-Meyers Squibb**
- C. Ulesfia™ Lotion (benzyl alcohol lotion) - Sciele Pharma, Inc.**

**New Indications for Existing Products**

The Committee reviewed the following new indications for existing products: [See product inserts for specific wording.]

- A. Avastin® (bevacizumab solution for intravenous infusion) Genentech** - For the treatment of metastatic renal cell carcinoma in combination with interferon alfa.
- B. Forteo® (teriparatide injection) Eli Lilly & Co** - For the treatment of men and women with glucocorticoid-induced osteoporosis at high risk for fracture.
- C. Invega® (paliperidone extended-release tablets) Janssen** - For the acute treatment of schizoaffective disorder as monotherapy, or as an adjunct to mood stabilizers and/or antidepressants.
- D. Isentress® (raltegravir tablets) Merck** - For use in combination with other anti-retroviral (ARV) agents for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients. Previously, Isentress was indicated for use in combination with other antiretroviral agents for treatment of HIV-1 infection in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents).
- E. Tekturna HCT® (aliskiren and hydrochlorothiazide tablets) Novartis** – For the treatment of hypertension as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.
- F. Tracleer® (bosentan tablets) Actelion** - For the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group 1) in patients with WHO Class II symptoms, to improve exercise ability and decrease the rate of clinical worsening.

**New Clinical Line Extensions**

The Committee reviewed the following new clinical line extensions.

- A. Acuvail™ (ketorolac tromethamine 0.45% preservative-free ophthalmic solution) - Allergan**
- B. Extavia® (interferon beta-1b for subcutaneous injection) - Novartis**
- C. Onsolis™ (fentanyl buccal soluble film) - Meda Pharmaceuticals**
- D. Plan B® One-Step (levonorgestrel tablet) - Duramed Pharmaceuticals**
- E. Sumavel™ DosePro™ (sumatriptan injection) - Zogenix, Inc**